Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bumble Inc (BMBL) vs Eli Lilly And Co (LLY) Price & Performance

Bumble IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Bumble Inc vs Eli Lilly And Co — how do they compare? Bumble Inc trades at $2.68 (market cap $366.87M), while Eli Lilly And Co trades at $1,204.03 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2943.8× Bumble Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.

BMBLLLY
Market Cap
$366.87M$1.08T
Sector
TechnologyHealth
52-Week High
$7.17$1.24K
52-Week Low
$2.70$639.43
Enterprise Value
$672.73M$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bumble Inc

BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.

The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY